• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从基于结构和配体的方法中获得的与HIV整合酶抑制相关的分子特征。

Molecular features related to HIV integrase inhibition obtained from structure- and ligand-based approaches.

作者信息

de Carvalho Luciana L, Maltarollo Vinícius G, de Lima Emmanuela Ferreira, Weber Karen C, Honorio Kathia M, da Silva Albérico B F

机构信息

Instituto de Química de São Carlos, Universidade de São Paulo, São Carlos, Brazil.

Centro de Ciências Naturais e Humanas, Universidade Federal do ABC, Santo André, Brazil.

出版信息

PLoS One. 2014 Jan 8;9(1):e81301. doi: 10.1371/journal.pone.0081301. eCollection 2014.

DOI:10.1371/journal.pone.0081301
PMID:24416129
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3885377/
Abstract

Among several biological targets to treat AIDS, HIV integrase is a promising enzyme that can be employed to develop new anti-HIV agents. The aim of this work is to propose a mechanistic interpretation of HIV-1 integrase inhibition and to rationalize the molecular features related to the binding affinity of studied ligands. A set of 79 HIV-1 integrase inhibitors and its relationship with biological activity are investigated employing 2D and 3D QSAR models, docking analysis and DFT studies. Analyses of docking poses and frontier molecular orbitals revealed important features on the main ligand-receptor interactions. 2D and 3D models presenting good internal consistency, predictive power and stability were obtained in all cases. Significant correlation coefficients (r(2) = 0.908 and q(2)= 0.643 for 2D model; r(2)= 0.904 and q(2)= 0.719 for 3D model) were obtained, indicating the potential of these models for untested compounds. The generated holograms and contribution maps revealed important molecular requirements to HIV-1 IN inhibition and several evidences for molecular modifications. The final models along with information resulting from molecular orbitals, 2D contribution and 3D contour maps should be useful in the design of new inhibitors with increased potency and selectivity within the chemical diversity of the data.

摘要

在治疗艾滋病的多个生物学靶点中,HIV整合酶是一种有前景的酶,可用于开发新型抗HIV药物。这项工作的目的是对HIV-1整合酶抑制作用提出一种机理解释,并阐明与所研究配体结合亲和力相关的分子特征。利用二维和三维定量构效关系模型、对接分析和密度泛函理论研究,对一组79种HIV-1整合酶抑制剂及其与生物活性的关系进行了研究。对接构象和前沿分子轨道分析揭示了主要配体-受体相互作用的重要特征。在所有情况下均获得了具有良好内部一致性、预测能力和稳定性的二维和三维模型。得到了显著的相关系数(二维模型的r(2) = 0.908和q(2)= 0.643;三维模型的r(2)= 0.904和q(2)= 0.719),表明这些模型对未测试化合物具有潜力。生成的全息图和贡献图揭示了HIV-1整合酶抑制的重要分子要求以及分子修饰的若干证据。最终模型以及分子轨道、二维贡献和三维等高线图所得到的信息,应有助于在数据的化学多样性范围内设计出具有更高效力和选择性的新型抑制剂。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38ec/3885377/f5ee194be145/pone.0081301.g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38ec/3885377/6a261a254508/pone.0081301.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38ec/3885377/486cd4caccbb/pone.0081301.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38ec/3885377/51c2f4a1bc21/pone.0081301.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38ec/3885377/599f61fa08b8/pone.0081301.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38ec/3885377/84b6ed54b6c8/pone.0081301.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38ec/3885377/1ac76f1e6d95/pone.0081301.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38ec/3885377/cc9b2597632a/pone.0081301.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38ec/3885377/7752779ea238/pone.0081301.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38ec/3885377/f5ee194be145/pone.0081301.g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38ec/3885377/6a261a254508/pone.0081301.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38ec/3885377/486cd4caccbb/pone.0081301.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38ec/3885377/51c2f4a1bc21/pone.0081301.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38ec/3885377/599f61fa08b8/pone.0081301.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38ec/3885377/84b6ed54b6c8/pone.0081301.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38ec/3885377/1ac76f1e6d95/pone.0081301.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38ec/3885377/cc9b2597632a/pone.0081301.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38ec/3885377/7752779ea238/pone.0081301.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38ec/3885377/f5ee194be145/pone.0081301.g009.jpg

相似文献

1
Molecular features related to HIV integrase inhibition obtained from structure- and ligand-based approaches.从基于结构和配体的方法中获得的与HIV整合酶抑制相关的分子特征。
PLoS One. 2014 Jan 8;9(1):e81301. doi: 10.1371/journal.pone.0081301. eCollection 2014.
2
Homology model-guided 3D-QSAR studies of HIV-1 integrase inhibitors.基于同源模建的 HIV-1 整合酶抑制剂的 3D-QSAR 研究。
J Chem Inf Model. 2012 Feb 27;52(2):515-44. doi: 10.1021/ci200485a. Epub 2012 Feb 7.
3
Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity.分子动力学方法估算 HIV-1 整合酶抑制剂的结合能,并与体外活性相关联。
Antimicrob Agents Chemother. 2012 Jan;56(1):411-9. doi: 10.1128/AAC.05292-11. Epub 2011 Oct 28.
4
QSAR studies of HIV-1 integrase inhibition.HIV-1整合酶抑制作用的定量构效关系研究。
Bioorg Med Chem. 2002 Dec;10(12):4169-83. doi: 10.1016/s0968-0896(02)00332-2.
5
Rational design of 2-pyrrolinones as inhibitors of HIV-1 integrase.设计 2-吡咯烷酮类化合物作为 HIV-1 整合酶抑制剂。
Bioorg Med Chem Lett. 2011 Nov 15;21(22):6724-7. doi: 10.1016/j.bmcl.2011.09.054. Epub 2011 Sep 20.
6
Diketoacid inhibitors of HIV-1 integrase: from L-708,906 to raltegravir and beyond.HIV-1 整合酶的二酮酸抑制剂:从 L-708,906 到拉替拉韦及其他药物。
Curr Med Chem. 2012;19(8):1177-92. doi: 10.2174/092986712799320565.
7
CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site.关于构象受限的肉桂酰HIV-1整合酶抑制剂的比较分子场分析(CoMFA)和比较分子相似性指数分析(CoMSIA)三维定量构效关系(3D QSAR)及对接研究:活性位点结合模式的探索
J Med Chem. 2002 Feb 14;45(4):841-52. doi: 10.1021/jm010399h.
8
Structural requirements for potential HIV-integrase inhibitors identified using pharmacophore-based virtual screening and molecular dynamics studies.使用基于药效团的虚拟筛选和分子动力学研究确定的潜在HIV整合酶抑制剂的结构要求。
Mol Biosyst. 2016 Mar;12(3):982-93. doi: 10.1039/c5mb00767d.
9
Exploring binding mode for styrylquinoline HIV-1 integrase inhibitors using comparative molecular field analysis and docking studies.使用比较分子场分析和对接研究探索苯乙烯基喹啉HIV-1整合酶抑制剂的结合模式。
Acta Pharmacol Sin. 2004 Jul;25(7):950-8.
10
Induced-fit docking approach provides insight into the binding mode and mechanism of action of HIV-1 integrase inhibitors.诱导契合对接方法有助于深入了解HIV-1整合酶抑制剂的结合模式和作用机制。
ChemMedChem. 2009 Sep;4(9):1446-56. doi: 10.1002/cmdc.200900166.

引用本文的文献

1
Understanding electrostatic and steric requirements related to hypertensive action of AT(1) antagonists using molecular modeling techniques.运用分子建模技术理解与血管紧张素Ⅱ1型(AT(1))拮抗剂的高血压作用相关的静电和空间要求。
J Mol Model. 2014 Jul;20(7):2231. doi: 10.1007/s00894-014-2231-7. Epub 2014 Jun 17.

本文引用的文献

1
Novel therapeutic strategies targeting HIV integrase.针对 HIV 整合酶的新型治疗策略。
BMC Med. 2012 Apr 12;10:34. doi: 10.1186/1741-7015-10-34.
2
A quantitative basis for antiretroviral therapy for HIV-1 infection.抗 HIV-1 感染的抗逆转录病毒治疗的定量基础。
Nat Med. 2012 Feb 19;18(3):446-51. doi: 10.1038/nm.2649.
3
Homology model-guided 3D-QSAR studies of HIV-1 integrase inhibitors.基于同源模建的 HIV-1 整合酶抑制剂的 3D-QSAR 研究。
J Chem Inf Model. 2012 Feb 27;52(2):515-44. doi: 10.1021/ci200485a. Epub 2012 Feb 7.
4
Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins.比较分子场分析(CoMFA)。1. 形状对类固醇与载体蛋白结合的影响。
J Am Chem Soc. 1988 Aug 1;110(18):5959-67. doi: 10.1021/ja00226a005.
5
Comparative docking and CoMFA analysis of curcumine derivatives as HIV-1 integrase inhibitors.姜黄素衍生物作为 HIV-1 整合酶抑制剂的比较对接和 CoMFA 分析。
Mol Divers. 2011 Aug;15(3):733-50. doi: 10.1007/s11030-011-9304-7. Epub 2011 Feb 15.
6
Insights into the molecular requirements for the anti-obesity activity of a series of CB1 ligands.揭示一系列 CB1 配体抗肥胖活性的分子需求。
Chem Biol Drug Des. 2010 Oct;76(4):320-9. doi: 10.1111/j.1747-0285.2010.01016.x. Epub 2010 Sep 2.
7
FDA notifications. FDA approves raltegravir for HIV-1 treatment-naive patients.美国食品药品监督管理局通知。美国食品药品监督管理局批准拉替拉韦用于初治的HIV-1感染患者。
AIDS Alert. 2009 Sep;24(9):106-7.
8
Docking-based 3D-QSAR study of HIV-1 integrase inhibitors.基于对接的 HIV-1 整合酶抑制剂的 3D-QSAR 研究。
Eur J Med Chem. 2009 Nov;44(11):4276-87. doi: 10.1016/j.ejmech.2009.07.010. Epub 2009 Jul 16.
9
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.发现雷特格韦,一种有效、选择性口服生物可利用的HIV整合酶抑制剂,用于治疗HIV-艾滋病感染。
J Med Chem. 2008 Sep 25;51(18):5843-55. doi: 10.1021/jm800245z.
10
Development of 2-t butyl-N-methyl pyrimidones as potent inhibitors of HIV integrase.2-叔丁基-N-甲基嘧啶酮作为HIV整合酶强效抑制剂的研发
Bioorg Med Chem Lett. 2008 Apr 15;18(8):2709-13. doi: 10.1016/j.bmcl.2008.03.017. Epub 2008 Mar 10.